Annals of Surgical Oncology

, Volume 15, Issue 8, pp 2350–2351 | Cite as

Bisphosphonate: A Novel Treatment for Pigmented Villonodular Synovitis

Bone and Soft Tissue Sarcomas

Keywords

Bisphosphonates Giant Cell Pamidronate Multinucleated Giant Cell Giant Cell Tumour 

References

  1. 1.
    Martin RC, Osborne DL, Edwards MJ, et al. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence. Oncol Rep 2000;7:413–9PubMedGoogle Scholar
  2. 2.
    Leutheuser W, Moll G, Schulz A. Localised (circumscribed) nodular synovitis. Arch Orthop Trauma Surg 1983;102:19–22PubMedCrossRefGoogle Scholar
  3. 3.
    Rosa MA, Galli M, Fada G. Proliferating cell nuclear antigen labelling index in localised pigmented villo-nodular synovitis and its relationship to the size of nodules. Int Orthop 2000;24:197PubMedCrossRefGoogle Scholar
  4. 4.
    Darling JM, Golding SR, Harada Y, et al. Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts. Am J Pathol 1997;150:1383–93PubMedGoogle Scholar
  5. 5.
    Yoshida W, Uzuki M, Kurose A, et al. Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol 2003; 34:65–73PubMedCrossRefGoogle Scholar
  6. 6.
    Lau YS, Sabokbar A, Gibbons CL, et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36:945–54PubMedCrossRefGoogle Scholar
  7. 7.
    Neale SD, Kristelly R, Gundle R, et al. Giant cells in pigmented villo nodular synovitis express an osteoclast phenotype. J Clin Pathol 1997;50:605–8PubMedCrossRefGoogle Scholar
  8. 8.
    Hu Y, Yu S. Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. Zhonghua Bing Li Xue Za Zhi 2002;31:128–31PubMedGoogle Scholar
  9. 9.
    Atkins GJ, Kostakis P, Vincent C, et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006;21:1339–49PubMedCrossRefGoogle Scholar
  10. 10.
    Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005;167:117–28PubMedGoogle Scholar
  11. 11.
    Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007;25:913–33PubMedCrossRefGoogle Scholar
  12. 12.
    Kavanagn KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci 2006;103:7829–34CrossRefGoogle Scholar
  13. 13.
    Coxan FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307–12CrossRefGoogle Scholar
  14. 14.
    Martini G, Gennari L, Merlotti D, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget’s disease of bone. Bone 2007;40:457–63PubMedCrossRefGoogle Scholar
  15. 15.
    Dobring H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006;17:693–703CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  1. 1.Department of Orthopaedic SurgeryShiraz University of Medical Science, Chamran HospitalShirazIran

Personalised recommendations